Share

January 2023; 10 (1) Research ArticleOpen Access

Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar

Ingo Kleiter, Anthony Traboulsee, Jacqueline Palace, Takashi Yamamura, Kazuo Fujihara, Albert Saiz, Adil Javed, David Mayes, H-Christian von Büdingen, Gaelle Klingelschmitt, Daniela Stokmaier, Jeffrey L. Bennett
First published December 8, 2022, DOI: https://doi.org/10.1212/NXI.0000000000200071
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1217

Share

Article Information

vol. 10 no. 1 e200071
DOI: 
https://doi.org/10.1212/NXI.0000000000200071
PubMed: 
36724181
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 28, 2022
  • Accepted in final form October 12, 2022
  • First Published December 8, 2022.
Copyright & Usage: 
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Ingo Kleiter, MD,
    2. Anthony Traboulsee, MD,
    3. Jacqueline Palace, DM,
    4. Takashi Yamamura, MD,
    5. Kazuo Fujihara, MD,
    6. Albert Saiz, MD,
    7. Adil Javed, MD,
    8. David Mayes, MChem,
    9. H-Christian von Büdingen, MD, PhD,
    10. Gaelle Klingelschmitt, PhD,
    11. Daniela Stokmaier, PhD and
    12. Jeffrey L. Bennett, MD, PhD
  1. Ingo Kleiter, MD,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Alexion, Biogen, Celgene, Horizon, Merck, Roche

    Editorial Boards:

    1. BMC Neurology, associate editor, since 2018<br><br>Neuroimmunology Reports, editorial board member, since 2020<br><br>Frontiers in Neurology, associate editor, since 2022<br><br>Frontiers in immunology, associate editor, since 2022

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Alexion, Almirall, Biogen, Celgene, Hexal, Horizon, Merck, Roche

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Anthony Traboulsee, MD,
    3. Scientific Advisory Boards:

    1. 1. Sanofi Genzyme (commercial)<br><br>2. Hoffman la Roche (commercial)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1. Sanofi Genzyme (commercial)<br><br>2. Biogen (commercial)<br><br>3. Hoffman la Roche (commercial)<br><br>4. Novartis (commercial)<br><br>5. Consortium of Multiple Sclerosis Centers (non profit)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Hoffman la Roche (commercial)<br><br>(2) Sanofi Genzyme (commercial)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Hoffman la Roche, <br><br>(2) Clene<br><br>(3) Sanofi Genzyme<br><br>(4) Abbott

    Research Support, Government Entities:

    1. (1) Multiple Sclerosis Society of Canada, Principal Investigator 2019 ongoing

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Hilton Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jacqueline Palace, DM,
    4. Scientific Advisory Boards:

    1. 1) Merck Serono <br>2) Roche <br>3) ARGENX <br>4) Novartis <br>5) UCB <br>6) Alexion <br>7)Janssen<br>8) Sanofi

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. All commercial (speakers/meetings honorarium last two <br>years)<br>1) Roche <br>2) Alexion <br>3) Chugai

    Editorial Boards:

    1. Lancet Neurology editorial advisorry committee member

    Patents:

    1. ISIS Innovation Ltd. To protect for the use of<br>metabolomics as a method to diagnose and stage disease in<br>multiple sclerosis. Patent ref P37347WO and licence <br>agreement Numares multimarker MS diagnostics

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Amplo

    Speakers' Bureaus:

    1. Please see 3 (speaker/meetings)

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. All commercial (support for research)<br>1) Amplo <br>2) UCB<br>3) Alexion<br>4)Medimmune

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Grant for research:<br>1) Multiple Sclerosis Society<br>4) SPARKS Great Ormond Street

    Stock/Stock Options/Board of Directors Compensation:

    1. Astra Zenica shares

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Patent ref P37347WO and licence agreement Numares <br>multimarker MS diagnostics

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Takashi Yamamura, MD,
    5. Scientific Advisory Boards:

    1. 1)Biogen Japan (2) Chugai Pharmaceutical Co., Ltd (3) Takeda <br>Pharamaceutical Co.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Novartis Pharma (2) Nihon Pharmaceutical Co., Ltd.,<br>(3) Santen Pharmaceutical Co., Ltd., (4) Abbott Japan Co.,<br>Ltd./Eisai Co., Ltd., (5) Biogen Japan, (6) Dainippon<br>Sumitomo Pharma Co., Ltd., (7) Bayer Holding Ltd., (8)<br>Astellas Pharma Inc. (9) Takeda Pharamaceutical Co.<br>(10) Mitsubishi-Tanabe Pharma Co., Ltd. (11) Alexion Pharma

    Editorial Boards:

    1. Clinical and Experimental Neuroimmunology, Editor, since 2010

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Ono Pharmaceutical Co., Ltd., (2) Chugai<br>Pharmaceutical Co., Ltd., (3) Teva Pharmaceutical K.K.,<br>(4) Mitsubishi Tanabe Pharma Corporation, (5) Asahi Kasei<br>Kuraray Medical CO., Ltd.<br>(6) Novartis Pharma

    Research Support, Government Entities:

    1. (1) Ministry of Health, Labour and Welfare of Japan, the<br>Health and Labour Sciences Research Grants <br>on Intractable Diseases (Neuroimmunological Diseases),<br>investigator, since 2010.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Kazuo Fujihara, MD,
    6. Scientific Advisory Boards:

    1. Serves on scientific advisory boards for Biogen, <br>Mitsubishi-Tanabe, Novartis, Roche/Chugai, Alexion, <br>VielaBio/Horizon Therapeutics, UCB, Abbvie and Japan Tobacco.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. has received funding for travel or speaker honoraria <br>from Roche/Chugai, Biogen, Novartis, Alexion, Teijin, <br>Mitsubishi-Tanabe, AsahiKasei Medical, Merck, Eisai,and <br>Takeda.

    Editorial Boards:

    1. Serve as an editorial board member of Clinical and <br>Experimental Neuroimmunology (2009-present), Frontiers in <br>Neurology (2017-present), Neurology: Neuroimmunology and <br>Neuroinflammation (2018-present), Multiple Sclerosis (2019-<br>present), Multiple Sclerosis and Related Disorders (2020-<br>present) and Neuroimmunology Reports (2021-present) and <br>advisory board member of Sri Lanka journal of Neurology.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. funded as the investigator by the Grants-in-Aid for <br>Scientific Research from the Ministry of Health, Welfare <br>and Labor of Japan (2010&#x0096;present).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Albert Saiz, MD,
    7. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. compensation for consulting services and speaker <br>honoraria from Merck-Serono, Biogen-Idec, Sanofi, Novartis, <br>Roche, Alexion, Janssen, and Horizon Therapeutics

    Editorial Boards:

    1. Editorial advisory borad member: Neurol Neuroimmunol <br>Neuroinflamm

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Adil Javed, MD,
    8. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Javed has been a consultant for Biogen, BMS, Serono, <br>Horizon, and Genentech.

    Speakers' Bureaus:

    1. Dr. Javed serves on the speaker's bureau for Biogen, BMS, <br>Serono, Horizon Therapeutics, and Genentech.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. David Mayes, MChem,
    9. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Employee of ApotheCom, London, UK, who received funding from <br>F. Hoffman-La Roche for medical writing assistance.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. H-Christian von Büdingen, MD, PhD,
    10. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) F. Hoffmann La-Roche, Basel, Switzerland, various <br>positions, since 2016

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. F. Hoffmann-La Roche, since 2016<b

    Legal Proceedings:

    1. NONE

  10. Gaelle Klingelschmitt, PhD,
    11. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. employee of F.Hoffmann-La Roche LTD

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Daniela Stokmaier, PhD and
    12. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Roche, Senior Clinical Scientist, 7 years

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Jeffrey L. Bennett, MD, PhD
    13. Scientific Advisory Boards:

    1. (1) Alexion (2) Roche (3) IMCYSE SA (4) Genentech (5) Horizon Therapeutics (6) <br>TG Therapeutics (7) EMD Serono

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. 1) Compositions and Methods for the Treatment of <br><br>Neuromyelitis Optica; novel blocking monoclonal therapy <br><br>for neuromyelitis optica: US Patent: 10,654,916

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Reistone-Bio. (2) Horizon Therapeutics, (3) Chugai Pharma USA, (4) <br>Mitsubishi Tanabe, (5) Alexion Pharmaceuticals, (6) Genentech, (7) Roche, (8) <br>Antigenomycs, (9) EMD Serono, (10) Beigene<br>Speakers' Bureaus: <br>(1) Alexion Pharmaceuticals

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. (1) Clene Nanomedicine, data safety monitoring board, (2) Roche, data safety <br>monitoring board

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Mallinckrodt Pharmaceuticals, (2) Novartis, (3) Alexion

    Research Support, Government Entities:

    1. (1) National Institutes of Health, R01NS115488, R01EY022936, R21EY032399, <br>Principal investigator, 2020-2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Guthy Jackson Charitable Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Aquaporumab, rights for future royalty payments

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Ruhr University Bochum (I.K.), Bochum, Germany, and Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; University of British Columbia (A.T.), Vancouver, Canada; John Radcliffe Hospital (J.P.), Oxford, United Kingdom; National Institute of Neuroscience (T.Y.), National Center of Neurology and Psychiatry, Tokyo, Japan; Fukushima Medical University School of Medicine (K.F.), Japan; Service of Neurology (A.S.), Hospital Clinic and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; University of Chicago Department of Neurology (A.J.), IL; ApotheCom (D.M.), London, United Kingdom; F. Hoffmann-La Roche Ltd (H.-C.B., G.K., D.S.), Basel, Switzerland; and Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Aurora.
  1. Correspondence
    Dr. Kleiter ingo.kleiter{at}ms-klinik.de
View Full Text

Article usage

Article usage: December 2022 to August 2023

AbstractFullPdfSource
Dec 202231132265Highwire
Jan 202320692228Highwire
Feb 202315589261Highwire
Mar 20239310116Highwire
Apr 20231420487Highwire
May 20231019784Highwire
Jun 20231415066Highwire
Jul 20231713756Highwire
Aug 2023612854Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me